Group 1 - The company reported an increase in revenue from RMB 0 million to RMB 6.0 million for the six months ending June 30, 2025, primarily driven by global sales of its new high-end cosmetics brand KOSHINé [1] - Research and development costs rose by RMB 9.3 million or 23.6% from RMB 39.3 million for the six months ending June 30, 2024, to RMB 48.6 million for the six months ending June 30, 2025, due to a focus on core dermatology pipelines KX-826 and GT20029 [1] - The company has five potential first-in-class/best-in-class drug candidates in clinical stages I-III and one new whitening ingredient KT-939, with significant progress in clinical trials for KX-826 and GT20029 in China [1] Group 2 - The company is in a transitional phase from research and development to commercialization of its cosmetics, planning to allocate more resources to explore various methods, including launching new products and increasing promotion in both domestic and overseas markets [2] - Future strategies include deepening partnerships with leading e-commerce platforms such as Tmall, JD.com, Douyin, Xiaohongshu, and Amazon, and establishing a diversified sales channel system [2] - The company aims to enhance customer resource expansion and loyalty through various promotional activities and refined membership management, including hosting exclusive member events and collaborating with selected KOLs and KOCs to accelerate online sales growth [2]

开拓药业-B(09939)公布2025年中期业绩，收益由去年同期0元增至600万元，净亏损8326.8万元，同比增 长16.47%;每股亏损0.19元。 公告称，收益增加主要由于全新高端化妆品品牌KOSHIN化妆品的全球销售。集团将持续探索不同的方 法，进一步推动公司化妆品在全球商业化。亏损增加主要由于集团研发成本及营销成本增加。 ...

Core Viewpoint - The company reported a significant increase in revenue for the first half of 2025, driven by the global sales of its new high-end cosmetics brand KOSHINÉ, despite an increase in net loss due to rising R&D and marketing costs [1] Financial Performance - Revenue increased from 0 to 6 million yuan compared to the same period last year [1] - Net loss amounted to 83.268 million yuan, representing a year-on-year increase of 16.47% [1] - Earnings per share reported a loss of 0.19 yuan [1] Strategic Initiatives - The company plans to continue exploring various methods to further commercialize its cosmetics globally [1]

[Announcement Summary](index=1&type=section&id=Announcement%20Summary) [Financial Highlights](index=2&type=section&id=Financial%20Highlights) H1 2025 revenue reached **RMB 6.0 million** from cosmetics sales, but net loss widened by **16.5%** to **RMB 83.3 million**, driven by increased R&D and marketing expenses H1 2025 Financial Highlights | Metric | For the six months ended June 30, 2025 (RMB million) | For the six months ended June 30, 2024 (RMB million) | Change (RMB million) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Revenue | 6.0 | 0.0 | 6.0 | N/A | | Net Loss | (83.3) | (71.5) | (11.8) | 16.5% | | R&D Costs | (48.6) | (39.3) | (9.3) | 23.6% | | Administrative Expenses | (25.2) | (33.9) | 8.7 | (25.6%) | | Marketing Costs | (8.3) | (1.8) | (6.5) | 369.0% | | Cash and Cash Equivalents (End of Period) | 52.9 | - | - | - | - The Board resolved **not to declare any interim dividend** for the six months ended June 30, 2025[3](index=3&type=chunk) [R&D Milestones and Achievements](index=3&type=section&id=R%26D%20Milestones%20and%20Achievements) The company's core dermatological pipelines, KX-826 and GT20029, achieved positive clinical progress in alopecia and acne indications, while new raw material KT-939 also launched global sales, forming a 'three-pronged' business model [KX-826](index=3&type=section&id=KX-826) KX-826 topical solution for Chinese alopecia showed positive topline data in long-term safety Phase III, combination therapy observation, and pivotal Phase II trials, demonstrating excellent safety and efficacy; Phase III has enrolled **666 patients**, expected to complete by early 2026 - KX-826 topical solution for Chinese alopecia's long-term safety Phase III clinical trial achieved topline data, meeting primary endpoints with statistically significant and clinically meaningful results, demonstrating excellent safety and efficacy[4](index=4&type=chunk) - The clinical observation study of KX-826 combined with minoxidil for Chinese adult male alopecia met its primary endpoint, aiming to optimize future formal Phase III clinical trial design[4](index=4&type=chunk) - KX-826 topical solution **1.0%** for alopecia's pivotal Phase II clinical trial achieved topline data, meeting primary endpoints with statistically significant and clinically meaningful results, demonstrating excellent efficacy and safety[4](index=4&type=chunk) - KX-826 topical solution **1.0%** for alopecia's pivotal Phase III clinical trial has completed enrollment of **666 patients**, expected to finish by early 2026[4](index=4&type=chunk) [AR-PROTAC Compound (GT20029)](index=4&type=section&id=AR-PROTAC%20Compound%20%28GT20029%29) GT20029 gel for acne's China Phase II clinical trial reported topline data, successfully meeting primary endpoints with excellent efficacy, safety, and PK characteristics, and determined the recommended Phase III dose at **0.5%** - AR-PROTAC compound GT20029 gel for acne's China Phase II clinical trial reported topline data, successfully meeting primary endpoints with excellent efficacy, safety, and PK characteristics, and determined the recommended Phase III dose at **0.5%**[5](index=5&type=chunk) [New Raw Material (KT-939)](index=4&type=section&id=New%20Raw%20Material%20%28KT-939%29) KT-939, a whitening and spot-reducing cosmetic active ingredient, completed its first sale, marking the launch of the company's B2B active cosmetic ingredient business and forming a 'three-pronged' business model - KT-939 as a whitening and spot-reducing cosmetic active ingredient completed its first sale, marking the launch of global sales for active ingredients[6](index=6&type=chunk) - The company has formed a 'three-pronged' business model encompassing B2B active cosmetic ingredient business, B2C active cosmetic product business, and topical innovative drug R&D business[6](index=6&type=chunk) [Management Discussion and Analysis](index=4&type=section&id=Management%20Discussion%20and%20Analysis) [Business Overview](index=4&type=section&id=Business%20Overview) The company is a clinical-stage innovative drug enterprise focused on dermatology and functional cosmetics, with 5 drug candidates in Phase I-III clinical trials; its cosmetics business complements drug R&D by providing funding and market data, with core products KX-826 and GT20029 advancing to Phase II/III and Phase II, respectively, and the high-end cosmetics brand KOSHINÉ launched in H2 2024 - The company is a clinical-stage innovative drug enterprise in China focused on addressing unmet clinical needs and extending into functional cosmetics[7](index=7&type=chunk) - The cosmetics business provides funding for drug R&D activities and market data for future drug sales strategies[7](index=7&type=chunk) - The company has **5** potential first-in-class/best-in-class drug candidates in Phase I-III clinical stages, with a pipeline primarily covering dermatological (e.g., alopecia, acne) and oncology indications[7](index=7&type=chunk) - In H2 2024, the company officially launched sales of its new high-end cosmetics brand KOSHINÉ, with a total of **eight** products currently on the market, including anti-hair loss liquid series, anti-acne cream, and whitening series[8](index=8&type=chunk) - The company has developed a multi-channel digital marketing strategy, expanding to traditional e-commerce platforms like Tmall and JD.com, actively deploying on emerging content-driven e-commerce platforms like Douyin and Xiaohongshu, and also expanding global sales channels such as Amazon US[8](index=8&type=chunk)[9](index=9&type=chunk) [Corporate Strategy and Product Pipeline](index=4&type=section&id=Corporate%20Strategy%20and%20Product%20Pipeline) The company's strategy focuses on dermatology and functional cosmetics, aiming to develop first-in-class/best-in-class drugs to address unmet clinical needs; the cosmetics business supports drug R&D with funding and market insights, with **5** drug candidates in Phase I-III clinical trials, and core products KX-826 and GT20029 in Phase II/III - The company is committed to becoming a leader in the research, development, and commercialization of innovative therapies and high-end cosmetics[7](index=7&type=chunk) - The pipeline primarily covers dermatological (e.g., alopecia, acne) and oncology indications, with cosmetic categories including anti-hair loss, anti-acne, and whitening products[7](index=7&type=chunk) - Two core products, KX-826 and GT20029, have advanced to Phase II/III and Phase II clinical trials, respectively[7](index=7&type=chunk) [Cosmetics Business Development and Marketing Strategy](index=5&type=section&id=Cosmetics%20Business%20Development%20and%20Marketing%20Strategy) Since H2 2024, the company officially launched sales of its high-end cosmetics brand KOSHINÉ, with eight products already on the market; through outsourced production and prioritizing online sales channels, the company implements multi-channel digital marketing strategies, including traditional e-commerce platforms and content-driven platforms, and actively expands into overseas markets like Amazon US, to enhance brand awareness and market penetration - The KOSHINÉ brand has launched **eight** products, including anti-hair loss liquid series, anti-acne cream, and whitening series, with the KX-826-based anti-acne cream and KT-939-based whitening series launched in early 2025[8](index=8&type=chunk) - The company outsources cosmetics production, prioritizes online sales channels, and has developed a multi-channel digital marketing strategy[8](index=8&type=chunk) - Through data-driven precise advertising, conversion rates on major platforms like Tmall Global, Douyin Flagship Store, and JD Worldwide have significantly improved[9](index=9&type=chunk) - The company highly values fostering deep consumer interaction on high-quality content platforms like Xiaohongshu and WeChat, achieving a closed-loop marketing model of 'content seeding—brand cultivation—sales conversion'[9](index=9&type=chunk) [Core Products and R&D Progress](index=6&type=section&id=Core%20Products%20and%20R%26D%20Progress) The company deeply focuses on AR targets in dermatology, with core products KX-826 and GT20029 achieving multiple positive clinical advancements in alopecia and acne indications, including completing several Phase II/III clinical trials and obtaining topline data; concurrently, other pipeline products such as GT1708F, ALK-1 antibody, GT0486, and c-Myc molecular glue have also progressed in oncology and other disease areas, and new raw material KT-939 has initiated commercialization - The company possesses a risk-balanced and diversified portfolio of drug candidates, committed to addressing numerous unmet clinical needs with significant market potential[13](index=13&type=chunk) - The company has developed **5** clinical-stage drugs and **1** new raw material, obtaining clinical trial approvals in China (including Taiwan), the US, and other countries and regions[14](index=14&type=chunk) [KX-826 (AR Antagonist)](index=8&type=section&id=KX-826%20%28AR%E6%8B%AE%E6%8A%97%E5%89%82%29) KX-826 is a topical AR antagonist that treats alopecia and acne by blocking the AR signaling pathway, holding patents globally; for alopecia, several China and US clinical trials showed excellent safety, efficacy, and statistical significance, with China's Phase III trial completing patient enrollment; for acne, China's Phase II trial demonstrated preliminary efficacy and good safety - KX-826 is a topical drug that blocks the AR signaling pathway, reducing the sensitivity of AR in hair follicles and sebaceous glands to androgens, thereby minimizing systemic side effects[14](index=14&type=chunk) - The company holds patents for KX-826 in multiple countries globally and in China, with the core patent valid until September 8, 2030

格隆汇8月15日丨开拓药业-B(09939.HK)公布，董事会会议将于2025年8月28日（星期四）举行，藉以 （其中包括）考虑及批准本公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 開拓藥業有限公司 ＊ KINTOR PHARMACEUTICAL LIMITED ( 於開曼群島註冊成立的有限公司 ) KINTOR PHARMACEUTICAL LIMITED 董事會主席、執行董事及行政總裁 童友之博士 香港，2025 年 8 月 15 日 於本公告日期，執行董事為童友之博士 及倪翔博士 ；非執行董事為高維鵬先生及衛舸 琪女士；及獨立非執行董事為徐敏博士、楊懷嚴先生及童亮教授。 * 僅供識別 - 1 - ( 股份代號 : 9939) 董事會會議日期 開拓藥業有限公司*（「本公司」）董事（「董事」）會（「董事會」）謹此公佈， 董事會會議將於 2025 年 8 月 28 日（星期四）舉行，藉以（其中包括）考慮及批准本 公司及其附屬公司截至 2025 年 6 月 30 日止六個月之中期業績及其發佈。 承董事會命 ...

开拓药业-B(09939)发布公告，配售事项已于2025年8月5日根据协议的条款及条件完成，配售代理成功 配售合共2067.3万股配售股份予不少于六名承配人，配售价为每股配售股份2.08港元。据董事经作出一 切合理查询后所深知、尽悉及确信，承配人及彼等的最终实益拥有人均为独立于本公司或其关连人士且 与彼等概无关连的第三方。 由于完成认购事项的所有条件已达成，本公司已于2025年8月14日根据协议的条款及条件，按每股认购 股份2.08港元(与配售价相等)向卖方配发及发行2067.3万股认购股份。 ...

由于完成认购事项的所有条件已达成，公司已于2025年8月14日根据协议的条款及条件，按每股认购股 份2.08港元（与配售价相等）向卖方配发及发行20,673,000股认购股份。 格隆汇8月14日丨开拓药业-B(09939.HK)公布，配售事项已于2025年8月5日根据协议的条款及条件完 成，配售代理成功配售合共20,673,000股配售股份予不少于六名承配人，配售价为每股配售股份2.08港 元。 ...

Core Viewpoint - The company completed a placement of 20.673 million shares at a price of HKD 2.08 per share, with all conditions for the subscription being met [1] Group 1 - The placement was successfully executed by the placement agent to no fewer than six subscribers [1] - The subscribers and their ultimate beneficial owners are independent of the company and its related parties [1] - The company issued the subscription shares on August 14, 2025, at the same price as the placement [1]

表格類別： 股票 狀態： 新提交 公司名稱： 開拓藥業有限公司* 呈交日期： 2025年8月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09939 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫 ...